PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 0.1% – What’s Next?

PharmaCyte Biotech Inc (OTCMKTS:PMCBDGet Free Report)’s share price fell 0.1% during mid-day trading on Friday . The stock traded as low as $0.5310 and last traded at $0.5402. 57,214 shares changed hands during mid-day trading, an increase of 548% from the average session volume of 8,831 shares. The stock had previously closed at $0.5405.

PharmaCyte Biotech Trading Down 0.1%

The business’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.69.

PharmaCyte Biotech Company Profile

(Get Free Report)

PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.

In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.

Further Reading

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.